FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Approves Mylans Generic Risperdal

[ Price : $8.95]

FDA approves Mylans ANDA for a generic form of Janssens Risperdal.

Boxed Warnings for Antipsychotics

[ Price : $8.95]

FDA announces August labeling changes to 41 drugs, including boxed warnings for 12 antipsychotics.

CDER Good Review Practices to Engage Industry Earlier

[ Price : $8.95]

CDER deputy director Douglas Throckmorton tells a regulatory affairs meeting that new policies under the Centers Good Review Manag...

Appeals Court Lifts Risperdal Exclusivity

[ Price : $8.95]

An appeals court panel says Teva is not entitled to marketing exclusivity for generic Risperdal in a patent-listing dispute.

Latest FDA Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites Concept Labs, Forest Labs, Drs. Foster and Smith, Hamilton Medical Center, Ovati...

Center Directors Support Critical Path

[ Price : $8.95]

FDA Center directors, participating in a roundtable discussion of the agencys Critical Path Initiative, provide anecdotal impressi...

CBER Advancing Electronic Labeling Submissions

[ Price : $8.95]

CBER senior program management officer Vada Perkins discusses mandatory electronic labeling submissions that become effective 10/1...

Complete Response on Fentora Indication

[ Price : $8.95]

FDA gives Cephalon a complete response letter to its sNDA for an expanded Fentora indication for non-cancer breakthrough pain.

Davanat NDA Data Submitted to FDA

[ Price : $8.95]

Pro-Pharmaceuticals submits Davanat clinical and manufacturing data to FDA to support its NDA for the colorectal cancer treatment.

FDA Approves Nausea Patch

[ Price : $8.95]

FDA approves ProStrakans Sancuso patch to control nausea and vomiting in chemotherapy patients.